新型抗肿瘤药物在EGFR-TKI耐药非小细胞肺癌中的研究进展  

Research progress of novel anti-tumor agents in EGFR-TKI resistant non-small cell lung cancer

作　　者：白连伟[1] 张良[2] 郝杰 张蕊[2] Bai Lianwei;Zhang Liang;Hao Jie;Zhang Rui(Third Department of Oncology,Jilin Cancer Hospital,Changchun 130000,China;First Department of Oncology,Jilin Cancer Hospital,Changchun 130000,China)

机构地区：[1]吉林省肿瘤医院内三科,长春130000 [2]吉林省肿瘤医院内一科,长春130000

出　　处：《中华转移性肿瘤杂志》2024年第6期632-636,共5页Chinese Journal of Metastatic Cancer

摘　　要：表皮生长因子受体(EGFR)突变型非小细胞肺癌治疗引领了精准医学的发展,第三代EGFR酪氨酸激酶抑制剂(TKI)是目前晚期非小细胞肺癌的标准治疗手段,但耐药仍不可避免,EGFR-TKI耐药后治疗策略是临床研究探索的热点。近些年,随着双特异性抗体和抗体偶联药物等新型抗肿瘤药物的研发,改写了EGFR-TKI耐药人群的治疗格局。创新型抗肿瘤药物展现了非常令人鼓舞的疗效和极具潜力的应用前景,为EGFR-TKI耐药人群带来了全新的治疗选择。本文聚焦于双特异性抗体和抗体偶联药物在EGFR-TKI耐药人群中的最新研究进展,展望新型抗肿瘤药物的研发趋势。Epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC)has led the development of precision medicine,and third-generation EGFR tyrosine kinase inhibitors(TKIs)are the current standard of care for advanced NSCLC,but resistance is still inevitable.The treatment strategy after EGFR-TKI resistance is a hot topic in current research.In recent years,with the development of new anti-tumor drugs such as bispecific antibodies and antibody-drug conjugates,the treatment pattern of EGFR-TKI resistant patients has been rewritten.Innovative anti-tumor drugs have shown very encouraging efficacy and great potential in application,bringing a new treatment option for EGFR-TKI resistant population.This article focuses on the latest research progress of bispecific antibodies and antibody-drug conjugates in EGFR-TKI resistant population,and looks into the future of the development trend of novel anti-tumor drugs.

关 键 词：非小细胞肺癌 表皮生长因子受体 双特异性抗体 抗体偶联药物 

分 类 号：R73[医药卫生—肿瘤]